J9046 Injection, bortezomib, dr. reddy's
Also known as: bortezomib, Dr. Reddy's
Intravenous injection of bortezomib (Dr. Reddy's brand), a proteasome inhibitor chemotherapy agent, dosed per 0.1 milligram.
In Plain Language
protein-blocking cancer drug; cellular cleanup inhibitor
Clinical Context
Brand-specific formulation of bortezomib for multiple myeloma and mantle cell lymphoma treatment.
RVU Information
CPT J9046 does not have a physician work RVU assigned by CMS. This is typical for supply, drug, and equipment codes — reimbursement is based on Average Sales Price (ASP), fee schedules, or payer contracts rather than the RVU system.
Billing & Documentation
J-codes represent drugs administered by a healthcare provider (not self-administered). Documentation must include the drug name, dosage, route of administration, and medical necessity. Most payers require the National Drug Code (NDC) on the claim. Bill the appropriate administration code (96365-96379) in addition to the drug code.
Specialties
Frequently Asked Questions
What is CPT code J9046?
CPT J9046 (Injection, bortezomib, dr. reddy's) is a J Codes (Drugs) code. Intravenous injection of bortezomib (Dr. Reddy's brand), a proteasome inhibitor chemotherapy agent, dosed per 0.1 milligram.
How is J9046 administered?
CPT J9046 is administered by a healthcare provider, typically via injection or infusion. Brand-specific formulation of bortezomib for multiple myeloma and mantle cell lymphoma treatment. It is used by Hematology/Oncology, Medical Oncology.
When is CPT J9046 used?
Brand-specific formulation of bortezomib for multiple myeloma and mantle cell lymphoma treatment.
Track This Code in RVU Edge
Log procedures, calculate wRVUs, and benchmark against MGMA data — all in one app.
CPT® is a registered trademark of the American Medical Association. Data sourced from CMS Physician Fee Schedule RVU26A. Descriptions, synonyms, and clinical context are original content by RVU Edge.